Charles River Cuts $300M as Revenue Falls in Growth Market
Charles River Laboratories announced $300 million in automation-driven cost savings through 2030, but trailing revenue fell 2.7% to $4.0 billion—signaling share loss in a market growing at 6.4% annual
Charles River Cuts $300M in Costs as Top Line Falls
NEW YORK, October 15 —
Charles River Laboratories International, Inc. (CRL) announced more than $300 million in automation-driven savings through 2027-30 at a September 24 investor event, a plan that must first offset shrinking revenue before it clears the company's $3.03 billion debt load. Trailing twelve-month revenue fell 2.7% to $4.0 billion, and insiders sold $26 million of stock in the same stretch.
- $300M+ in automation savings expected 2027-30; announced at September 24 investor event.
- Trailing revenue $4.0B; 2.7% year-over-year contraction; GAAP net loss $4.85 per share TTM.
- $26.03M in insider sales over 90 days; zero open-market purchases; Director James C. Foster sold $17.97M.
The Market Is Growing. CRL's Revenue Is Not.
Charles River has beaten adjusted EPS estimates in each of its four most recent quarters while revenue contracted, a split the $300 million automation program is designed to extend rather than repair. CRL's three business units, Research Models and Services (lab animals, genetically engineered models, cell therapies), Discovery and Safety Assessment (toxicology, pharmacokinetics, bioanalysis), and Manufacturing Solutions (pharmaceutical and biologics QC testing), compete in a CRO market growing at 6.4% annually toward $63.3 billion by 2032. Revenue falling in a growing market is a share-loss signal, not a cycle story.
No Insider Bought a Share
The selling wave began August 5, the same day CRL released quarterly results, and continued through October 5. Director James C. Foster led the group: $7.90 million on August 10, then $10.07 million on August 25, for a combined $17.97 million. CEO Birgit Girshick sold $1.82 million on August 11. Each transaction was paired with a same-day option exercise, which is standard practice. CEVP Shannon Parisotto's pattern is more deliberate: four separate sales at successively higher prices from $263.00 on August 5 to $308.44 on October 5 read as continuous distribution, not a one-time liquidity event.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| CRL | $14.7B | 24.1x | +72.6% |
| TECH | $11.4B | 31.4x | +17.7% |
| IQV | $44.4B | 18.7x | +27.3% |
| COO | $10.8B | 12.1x | -23.3% |
| BIO | $9.8B | 36.9x | +16.0% |
| WST | $26.9B | 38.3x | +40.2% |
What Has to Be True for 24.1x to Hold
Four consecutive adjusted EPS beats (the most recent a 10.2% beat at $3.02 versus a $2.74 estimate) show that CRL's cost discipline is real, and $469 million in trailing free cash flow provides genuine debt-service capacity, a figure worth stress-testing in the DCF calculator against a prolonged revenue contraction scenario. At 24.1x forward adjusted earnings, the stock prices in either revenue stabilization or savings acceleration. Neither is confirmed. The specific number to watch: any sign of organic revenue growth in the next earnings report. Run the free Charles River Laboratories International, Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What cost cuts did Charles River Laboratories announce?
Charles River announced more than $300 million in automation-driven savings through 2027-30, unveiled at a September 24 investor event. The company is deploying cost discipline to offset shrinking revenue.
Why is Charles River losing market share?
Charles River's trailing twelve-month revenue fell 2.7% to $4.0 billion while the CRO market grew 6.4% annually toward $63.3 billion by 2032. Revenue contraction in a growing market signals share loss, not a cyclical downturn.
How many quarters has Charles River beaten earnings?
Charles River has beaten adjusted EPS estimates in each of its four most recent quarters, with the latest a 10.2% beat at $3.02 versus a $2.74 estimate. This demonstrates real cost discipline and debt-service capacity via $469 million in trailing free cash flow.
Why are insiders selling Charles River shares?
Insiders sold $26.03 million over 90 days with zero open-market purchases, beginning August 5 when CRL released quarterly results. Director James C. Foster sold $17.97 million total, and CEVP Shannon Parisotto sold at successively higher prices from $263.00 to $308.44, suggesting continuous distribution.
What must be true for CRL's 24.1x valuation to hold?
At 24.1x forward adjusted earnings, the stock prices in either organic revenue stabilization or accelerating cost savings. The specific metric to watch is any sign of organic revenue growth in the next earnings report.
Charles River Laboratories disclosed more than $300 million in expected savings from automating and simplifying its operations through 2027–30, announced at a September 24 investor event. The plan arrives as CRL's trailing twelve-month revenue has contracted 2.7% to $4.0 billion, raising the question of whether cost discipline can sustain profitability when the top line is shrinking.